Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

PLRX Total Debt

Short-term and long-term borrowings combined.

Pliant Therapeutics, Inc.NASDAQ: PLRX

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 52.2% from a year ago

Total debt stood at $28.78M at the end of Q1 FY2026, down 52.2% from a year earlier and down 1.1% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.

Context

  • Total debt amounted to 14.2% of total assets at the end of Q1 FY2026, down 3.2 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -52.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.78M-1.1% QoQ
Last fiscal yearDec 2025
$29.11M-51.6% YoY
Year agoMar 2025
$60.17M-52.2% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.2%——
1 year-51.6%——
3-year CAGR+22.5%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
29.11M USD
Year-over-year change
-51.6%
4-year CAGR
+41.8%

Total Debt vs competitors

How PLRX compares with its peers on the latest reported figures

  • PLRX's Mar 2026 total debt of $28.78M is the 4th highest of the 10 companies compared; the peer median is $13.63M.
  • Its year-over-year change of -52.2% is the 7th highest of 8, against a peer median of -8.3%.
  • Total debt amounts to 14.2% of total assets for PLRX, versus a peer median of 9.7%.
PLRX Competitors Peer median
Total Debt for PLRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GUTSFractyl Health, Inc. Common StockMar 2026$60.82M -1.0%-41.4%61.2%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$38.65M -8.3%-5.8%15.3%
MGNXMacroGenics, Inc.Mar 2026$36.51M -2.6%+45.3%16.8%
PLRXPliant Therapeutics, Inc.Mar 2026$28.78M -52.2%+22.5%14.2%
CLNNClene Inc.Mar 2026$22.05M +5.3%-12.0%101.8%
STROSutro Biopharma, Inc.Mar 2026$13.63M -36.3%-34.2%5.6%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$10.26M -26.7%-17.4%9.7%
OVIDOvid Therapeutics Inc.Mar 2026$1.46M -89.9%-6.7%0.6%
WHWKWhitehawk Therapeutics IncMar 2026$0 ——0.0%
COYACoya Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding PLRX) $13.63M-8.3%-12.0%9.7%

Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents51.67M33.69M63.23M71.19M45.45M
Short-term Investments148.93M297.5M431.01M284.54M145.5M
Net Receivables2.47M3.14M3M2.3M823K
Inventory00000
Other Current Assets156K173K1.27M163K1.13M
Total Current Assets209.44M340.31M505.5M362.26M196.45M
Property, Plant & Equipment (Net)10.94M9.91M4.78M32.77M25.01M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets838K394K1.87M1.92M3.77M
Total Non-current Assets11.77M10.3M6.65M34.69M28.78M
Total Assets221.22M350.61M512.15M396.95M225.23M
Account Payables2.97M1.58M4.53M5.96M480K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities5.22M7.2M9.04M11.15M8.3M
Total Current Liabilities16.83M23.91M28.52M33.22M16.37M
Long-term Debt09.93M10.05M30.21M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities5.33M13.36M10.05M59.65M27.66M
Total Liabilities22.16M37.27M38.58M92.87M44.02M
Common Stock3K5K6K6K6K
Retained Earnings(215.09M)(338.41M)(499.75M)(710.05M)(859.4M)
Accumulated OCI(201K)(1.96M)345K321K(15K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity199.06M313.34M473.58M304.08M181.21M
Total Debt7.19M15.82M11.37M60.19M29.11M
Net Debt(44.47M)(17.87M)(51.86M)(11M)(16.34M)

Pliant Therapeutics, Inc.

NASDAQ:PLRX

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.